63-92-3 Usage
Air & Water Reactions
Light sensitive and may be sensitive to exposure to air . Insoluble in water.
Mechanism of action
Phenoxybenzamine hydrochloride is a noncompetitive alpha-adrenergicreceptor blocker, and its action cannot be nullified by increasing the amount of agonist, or agonists. It causes epinephrine reversal in that the administration of epinephrine after pretreatment with phenoxybenzamine elicits vasodilation, and, conversely, phenoxybenzamine reverses epinephrine-mediated vasoconstriction to vasodilation. It may inhibit neuronal and extraneuronal uptake mechanisms of norepinephrine. At higher concentrations, it inhibits responses to 5-HT, histamine and acetylcholine.
Clinical Use
Oral phenoxybenzamine is used for the preoperativemanagement of patients with pheochromocytoma and in thechronic management of patients whose tumors are notamenable to surgery. Only about 20% to 30% of an oraldose is absorbed.
Side effects
The adverse effects of phenoxybenzamine include nasal congestion, miosis, postural hypotension, tachycardia, and inhibition of ejaculation.
Safety Profile
Confumed carcinogen
with experimental carcinogenic and
teratogenic data. Poison by intraperitoneal,intravenous, and subcutaneous routes.
Human systemic effects by ingestion:
changes in tubules, including acute renal
failure, acute tubular necrosis. Moderately
toxic by ingestion. Other experimental
reproductive effects. Mutation data
reported. A long-acting adrenergic blocker.
When heated to decomposition it emits very
toxic fumes of NOx and Cl-.
Synthesis
Phenoxybenzamine, N-(2-chloroethyl)-N-(1-methyl-2-phenoxyethyl)
benzylamine (12.2.5), is synthesized by reacting phenol with propylenoxide, which forms
1-phenoxy-2-propanol (12.2.1), the chlorination of which with thionyl chloride gives
1-phenoxy-2-propylchloride (12.2.2). Reacting this with 2-aminoethanol leads to formation of
1-phenoxy-2-(2-hydroxyethyl)aminopropane (12.2.3). Alkylation of the secondary amino
group gives N-(2-hydroxyethyl)-N-(1-methyl-2-phenoxyethyl)benzylamine (12.2.4), the
hydroxyl group of which is chlorinated using thionyl chloride, giving phenoxybenzamine
(12.2.5) [31].
Veterinary Drugs and Treatments
Phenoxybenzamine is used in small animals primarily for its effect
in reducing internal urethral sphincter tone in dogs and cats when
urethral sphincter hypertonus is present. It can also be used to treat
the hypertension associated with pheochromocytoma prior to surgery
or as adjunctive therapy in endotoxicosis.
In horses, phenoxybenzamine has been used for preventing or
treating laminitis in its early stages and to treat secretory diarrheas.
Drug interactions
Dibenzyline (phenoxybenzamine hydrochloride) may interact with compounds that stimulate both alpha- and beta-adrenergic receptors (i.e., epinephrine) to produce an exaggerated hypotensive response and tachycardia.
Carcinogenicity
Phenoxybenzamine hydrochloride is reasonably anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity from studies in experimental animals.
Metabolism
Metabolised in the liver and excreted in the urine and bile,
but small amounts remain in the body for several days.
Dosage
Initially, 10 mg of Dibenzyline (phenoxybenzamine hydrochloride) twice a day. Dosage should be increased every other day, usually to 20 to 40 mg 2 or 3 times a day, until an optimal dosage is obtained, as judged by blood pressure control.
Check Digit Verification of cas no
The CAS Registry Mumber 63-92-3 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 6 and 3 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 63-92:
(4*6)+(3*3)+(2*9)+(1*2)=53
53 % 10 = 3
So 63-92-3 is a valid CAS Registry Number.
InChI:InChI=1/C18H22ClNO/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17/h2-11,16H,12-15H2,1H3/p+1
63-92-3Relevant articles and documents
A PROCESS FOR THE PREPARATION OF PHENOXYBENZAMINE
-
Page/Page column 10; 12, (2018/08/03)
The present invention provides a process for the preparation of N-phenoxyisopropyl ethanolamine of Formula (II) and its conversion to Phenoxybenzamine of Formula (I) or pharmaceutically acceptable salts thereof.
COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING SALT SENSITIVITY OF BLOOD PRESSURE
-
, (2015/02/05)
To characterize the urinary exosome miRNome, microarrays were used to identify the miRNA spectrum present within urinary exosomes from ten individuals that were previously classified for their salt sensitivity status. The present application discloses distinct patterns of selected exosomal miRNA expression that were different between salt-sensitive (SS), salt-resistant (SR), and inverse salt-sensitive (ISS) individuals. These miRNAs can be useful as biomarkers either individually or as panels comprising multiple miRNAs. The present invention provides compositions and methods for identifying, diagnosing, monitoring, and treating subjects with salt sensitivity of blood pressure. The applications discloses panels of miRNAs useful for comparing profiles, and in some cases one or more of the miRNAs in a panel can be used. The miRNAs useful for distinguishing SS and SR or ISS and SR subjects. One or more of the 45 miRNAs can be used. Some of the miRNAs have not been previously reported to be circulating. See those miRNAs with asterisks in FIG. 1 and below. The present invention encompasses the use of one or more of these markers for identifying and diagnosing SR, SS, and ISS subjects.
